Sudarshan Pharma

Mumbai, India Founded: 2008 • Age: 18 yrs Listed
Sudarshan Pharma is engaged in manufacturing pharmaceuticals and specialty chemicals.

About Sudarshan Pharma

Sudarshan Pharma is a publicly listed company based in Mumbai (India) founded in 2008. Sudarshan Pharma is engaged in manufacturing pharmaceuticals and specialty chemicals. It operates on a B2B2C and Reseller / Distribution model. The company has 24 employees. Sudarshan Pharma has completed 1 acquisition, including Ishwari Healthcare. Its Indian entity Sudarshan Pharma Industries Limited reported revenue of β‚Ή712 Cr. Sudarshan Pharma offers products and services including Specialty Chemicals, API Manufacturing, Contract Manufacturing, and Intermediates Manufacturing. Its focus areas include Pharmaceuticals, Active Pharmaceutical Ingredients, Chemicals and Specialty Chemicals.

Company details

Sudarshan Pharma Industries Limited is involved in the production of pharmaceuticals and specialty chemicals. Operations are focused on active pharmaceutical ingredients (API), intermediates, and contract manufacturing. The company serves various sectors including healthcare and industrial applications. Solutions are provided for ethical divisions, generic supply, and institutional markets. Manufacturing facilities are located across multiple states in India, with distribution outlets in key regions. Exports of APIs and formulations are also managed to international markets.

  • Headquarters Mumbai, India
  • Employees 24
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website sudarshanpharma.com
  • Social LinkedIn X Facebook
  • Legal Name Sudarshan Pharma Industries Ltd
Key Metrics
  • Market Cap
    ₹800 Cr

    SUDARSHAN · NSE

  • Share Price
    ₹31.42

    -0.10% today

  • Revenue
    ₹703 Cr

    FY 2025-26 · +39.2% YoY

  • EBITDA
    ₹51.32 Cr

    Margin 7.3%

  • Net Profit
    ₹23.31 Cr

    FY 2025-26 · +29.3% YoY

  • P/E (TTM)
    28.7x

    P/B 4.3x

  • ROE
    16.3%

    ROCE 15.1%

  • Debt / Equity
    1.60

    Interest cover 54.1x

  • Latest Funding Round
    $449.92K (USD), Post-IPO

    Dec 2024

  • Employee Count
    24
  • Investments & Acquisitions

Products & Services of Sudarshan Pharma

Sudarshan Pharma offers a comprehensive portfolio of products and services, including Specialty Chemicals, API Manufacturing, Contract Manufacturing, and Intermediates Manufacturing.

Specialty Chemicals
Chemicals

Specialty chemicals are manufactured for diverse industrial applications.

API Manufacturing
Pharmaceuticals

Active pharmaceutical ingredients are produced for medicinal purposes.

Contract Manufacturing
Pharmaceuticals

Manufacturing services are provided for pharmaceutical and chemical products.

Intermediates Manufacturing
Chemicals

Chemical intermediates are produced for further industrial processing.

Funding Insights of Sudarshan Pharma

  • Total Rounds 1
  • Last Round Post-IPO β€” $449,920
  • First Round $449,920

    (Dec 2024)

All 1 funding rounds of Sudarshan Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2024$449,920Post-IPO––
–

Board of directors of Sudarshan Pharma Industries Limited (Sudarshan Pharma)

Sudarshan Pharma Industries Limited is the primary company behind Sudarshan Pharma. The board of Sudarshan Pharma Industries Limited currently have 7 directors; the longest-serving is Sachin Vasantrai Mehta, appointed in 2008. 18 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sachin Vasantrai Mehta
DIN 02211178
Managing Director23 Jul 200818 yrs 3 moSudarshan Pharma Industries Limited
Hemal Vasantrai Mehta
DIN 02211121
Managing Director16 Jan 201511 yrs 10 moSudarshan Pharma Industries Limited
Jaya Ankur Singhania
DIN 01990322
Director27 Dec 20223 yrs 10 moSudarshan Pharma Industries Limited
Rushabh Prashant Patil
DIN 09779021
Director21 Jul 20233 yrs 3 moSudarshan Pharma Industries Limited
Anil Balkrishna Ghogare
DIN 00432659
Director10 Nov 20233 yrsSudarshan Pharma Industries Limited
Vijay Ojha
DIN 02216129
Director18 Oct 20251 yr 1 moSudarshan Pharma Industries Limited
Vinay Kumar Pandey
DIN 10084203
Director01 May 20266 moSudarshan Pharma Industries Limited

People of Sudarshan Pharma

2 people are tracked at Sudarshan Pharma (2 in leadership); the tracked headcount is 24.

NameRoleGroup
Managing DirectorLeadership
Managing DirectorLeadership
Premium access

Complete people profiles for Sudarshan Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Sudarshan Pharma

Sudarshan Pharma is a publicly listed company on the BSE with ticker symbol SUDARSHAN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date22 Mar 2023
  • Listed onBSE: 543828
  • Listed entitySudarshan Pharma Industries Ltd
  • Exchange sectorHealth technology
  • ISININE00TV01023
  • Share price₹37.31 (-0.43% on the day) · 2026-10-14
  • Market capitalisation₹935 Cr
  • Price to earnings35.2
  • EPS (diluted, trailing year)₹1.06
  • Volume (last session)24,000

Financials of Sudarshan Pharma

Exchange-reported figures of Sudarshan Pharma Industries Limited, the listed company behind Sudarshan Pharma (NSE: SUDARSHAN).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹703 Cr
+39.2% YoY
EBITDA
₹51.32 Cr
+38.3% YoY
Profit After Tax
₹23.31 Cr
+29.3% YoY
Net Worth
₹155 Cr
+17.7% YoY
Total Assets
₹442 Cr
+44.0% YoY
Total Debt
₹285 Cr
+63.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue703505464461357193148
Revenue growth+39.2%+9.0%+0.5%+29.2%+84.7%+30.7%-
EBITDA51.3237.1122.8114.6810.927.164.76
EBITDA margin+7.3%+7.4%+4.9%+3.2%+3.1%+3.7%+3.2%
Profit before tax30.5421.6415.249.497.133.571.71
Net profit23.3118.0311.467.215.322.661.27
Net profit margin+3.3%+3.6%+2.5%+1.6%+1.5%+1.4%+0.9%
EPS (β‚Ή)0.970.664.762.925.382.801.34
Balance sheet
Total assets44230721713560.4152.3540.66
Net worth15513211210129.7822.5119.84
Total debt28517510534.1030.6029.7720.81
Cash & bank1.130.550.1411.720.241.251.27
Net working capital29122617410152.6240.8629.38
Cash flow
Cash from operations(2.30)(32.32)6.01(28.79)(3.82)2.770.51
Cash from investing(76.29)(20.62)(5.49)(25.65)(1.46)(1.29)(2.53)
Cash from financing79.1753.35(12.10)65.934.26(1.49)(0.28)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue217174221168169145162116
Revenue growth (YoY)+28.5%+20.1%+36.7%+45.3%+31.3%+46.4%--
Other income1.931.224.131.521.861.210.840.51
EBITDA20.5815.9020.2010.879.2111.0414.287.98
EBITDA margin+9.5%+9.1%+9.1%+6.5%+5.5%+7.6%+8.8%+6.9%
Depreciation1.361.411.090.910.900.880.830.63
Interest10.368.217.536.285.945.964.404.00
Profit before tax10.797.5015.715.204.235.419.893.86
Tax3.021.904.311.050.361.452.480.96
Net profit7.775.6011.404.153.873.967.412.90
EPS (β‚Ή)0.310.230.470.180.160.160.290.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue668503466461357193148
Revenue growth+32.8%+7.9%+0.9%+29.2%+84.7%+30.7%-
EBITDA48.9735.6922.5914.6810.937.284.76
EBITDA margin+7.3%+7.1%+4.9%+3.2%+3.1%+3.8%+3.2%
Profit before tax28.6621.3015.089.497.143.581.71
Net profit21.9717.9811.347.215.332.671.27
Net profit margin+3.3%+3.6%+2.4%+1.6%+1.5%+1.4%+0.9%
EPS (β‚Ή)0.900.664.722.935.392.801.34
Balance sheet
Total assets43630821913560.4052.3040.66
Net worth15313111210129.7822.5119.84
Total debt28217710734.1030.5929.7820.81
Cash & bank0.110.390.1311.710.231.151.27
Net working capital28622917310152.5140.7229.38
Cash flow
Cash from operations(2.75)(33.18)9.69(28.79)(3.70)2.670.51
Cash from investing(79.71)(20.24)(9.08)(25.65)(1.54)(1.35)(2.53)
Cash from financing82.1853.68(12.18)65.934.31(1.44)(0.28)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue205166200158167142162116
Revenue growth (YoY)+22.8%+16.4%+23.7%+37.0%+35.1%+39.9%--
Other income1.841.353.211.692.091.410.910.57
Total expenses184149182148157132148108
EBITDA20.7016.2718.3010.779.6110.2813.567.96
EBITDA margin+10.1%+9.8%+9.2%+6.8%+5.8%+7.2%+8.4%+6.9%
Depreciation1.261.291.000.810.810.790.760.66
Interest10.358.197.276.246.075.714.444.05
Profit before tax10.938.1413.245.414.825.199.273.82
Tax3.142.103.691.110.431.462.251.08

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue217174221168169145162116
Revenue growth (YoY)+28.5%+20.1%+36.7%+45.3%+31.3%+46.4%--
Other income1.931.224.131.521.861.210.840.51
EBITDA20.5815.9020.2010.879.2111.0414.287.98
EBITDA margin+9.5%+9.1%+9.1%+6.5%+5.5%+7.6%+8.8%+6.9%
Depreciation1.361.411.090.910.900.880.830.63
Interest10.368.217.536.285.945.964.404.00
Profit before tax10.797.5015.715.204.235.419.893.86
Tax3.021.904.311.050.361.452.480.96
Net profit7.775.6011.404.153.873.967.412.90
EPS (β‚Ή)0.310.230.470.180.160.160.290.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue703505464461357193148
Revenue growth+39.2%+9.0%+0.5%+29.2%+84.7%+30.7%-
Other income8.712.522.611.120.460.380.02
Total expenses652468441447346186143
Employee cost0.003.452.682.081.681.381.50
EBITDA51.3237.1122.8114.6810.927.164.76
EBITDA margin+7.3%+7.4%+4.9%+3.2%+3.1%+3.7%+3.2%
Depreciation3.792.221.240.910.870.740.35
Interest25.7015.778.945.403.383.232.72
Profit before tax30.5421.6415.249.497.133.571.71
Tax7.165.683.782.461.880.910.44
Net profit23.3118.0311.467.215.322.661.27
Net profit margin+3.3%+3.6%+2.5%+1.6%+1.5%+1.4%+0.9%
EPS (β‚Ή)0.970.664.762.925.382.801.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.0724.0724.0724.079.759.559.55
Reserves & surplus12710487.6476.9120.0312.9610.29
Shareholders' funds (net worth)15513211210129.7822.5119.84
Minority interest1.220.000.000.000.000.050.00
Secured loans22614768.9831.0427.384.3614.70
Unsecured loans59.3827.2335.863.063.2225.416.11
Total debt28517510534.1030.6029.7720.81
Total liabilities44230721713560.4152.3540.66
Assets
Gross block11050.3129.3322.458.497.646.32
Net block10447.5025.5019.896.466.225.64
Capital work in progress3.4422.541.880.010.540.000.00
Investments0.001.6713.8412.340.000.000.04
Inventories21914085.7474.5746.8723.9617.38
Sundry debtors23315312381.5173.4860.3926.87
Cash & bank balances1.130.550.1411.720.241.251.27
Loans & advances37.0532.1431.6430.839.002.031.34
Total current assets49032624019913087.6346.86
Total current liabilities20099.3366.4897.1676.9746.7717.48
Net working capital29122617410152.6240.8629.38
Total assets44230721713560.4152.3540.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.550.1411.720.241.251.273.56
Net cash from operating activities(2.30)(32.32)6.01(28.79)(3.82)2.770.51
Net cash from investing activities(76.29)(20.62)(5.49)(25.65)(1.46)(1.29)(2.53)
Net cash from financing activities79.1753.35(12.10)65.934.26(1.49)(0.28)
Net change in cash0.580.41(11.58)11.48(1.02)(0.01)(2.29)
Closing cash1.130.550.1411.720.241.251.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+39.2%+9.0%+0.5%+29.2%+84.7%+30.7%-
EBITDA growth+38.3%+62.7%+55.4%+34.4%+52.5%+50.4%-
PBT growth+52.4%+31.5%+60.6%+33.1%+99.7%+108.8%+9997.0%
Net income growth+29.3%+57.3%+59.0%+35.5%+100.0%+109.5%-
Revenue CAGR (3Y)+15.1%+12.3%+33.8%+46.1%---
EBITDA CAGR (3Y)+51.8%+49.2%+47.1%+45.6%---
Profitability & leverage
Net income margin+3.3%+3.0%+2.5%+1.5%+1.5%+1.4%+0.9%
Return on capital employed+15.1%+14.9%+13.7%+15.2%+18.7%+14.6%+10.9%
Return on net worth+16.3%+14.0%+10.8%+10.8%+20.1%+12.6%+6.5%
Debt / equity1.601.150.650.491.151.191.05
Long-term debt / equity0.150.100.110.140.200.290.35
Interest cover54.0848.0041.4539.2233.6350.3161.68
Efficiency & per share
Fixed asset turnover8.7812.6817.9029.8244.2827.7023.41
Inventory turnover3.914.475.787.6010.089.358.51
Debtors turnover3.643.674.545.955.334.435.51
EPS (β‚Ή)0.970.624.762.925.382.801.34
Dividend per share (β‚Ή)0.000.000.000.300.000.000.00
Book value per share (β‚Ή)6.295.3246.4241.9630.5423.5820.78
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue205166200158167142162116
Revenue growth (YoY)+22.8%+16.4%+23.7%+37.0%+35.1%+39.9%--
Other income1.841.353.211.692.091.410.910.57
Total expenses184149182148157132148108
EBITDA20.7016.2718.3010.779.6110.2813.567.96
EBITDA margin+10.1%+9.8%+9.2%+6.8%+5.8%+7.2%+8.4%+6.9%
Depreciation1.261.291.000.810.810.790.760.66
Interest10.358.197.276.246.075.714.444.05
Profit before tax10.938.1413.245.414.825.199.273.82
Tax3.142.103.691.110.431.462.251.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue668503466461357193148
Revenue growth+32.8%+7.9%+0.9%+29.2%+84.7%+30.7%-
Other income8.402.882.751.120.460.270.02
Total expenses619467443447346186143
Employee cost0.003.122.542.081.681.381.50
EBITDA48.9735.6922.5914.6810.937.284.76
EBITDA margin+7.3%+7.1%+4.9%+3.2%+3.1%+3.8%+3.2%
Depreciation3.411.311.230.910.870.740.35
Interest25.3015.969.035.403.383.232.72
Profit before tax28.6621.3015.089.497.143.581.71
Tax6.695.413.742.461.880.910.44
Net profit21.9717.9811.347.215.332.671.27
Net profit margin+3.3%+3.6%+2.4%+1.6%+1.5%+1.4%+0.9%
EPS (β‚Ή)0.900.664.722.935.392.801.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.0724.0724.0724.079.759.559.55
Reserves & surplus12510387.5576.9220.0312.9610.29
Shareholders' funds (net worth)15313111210129.7822.5119.84
Secured loans22414768.9831.4027.3825.7214.70
Unsecured loans58.2229.2637.912.703.214.066.11
Total debt28217710734.1030.5929.7820.81
Total liabilities43630821913560.4052.3040.66
Assets
Gross block99.5045.0324.3622.458.497.646.32
Net block94.2542.3320.5719.896.466.225.64
Capital work in progress3.4422.541.880.010.540.000.00
Investments7.754.8416.9412.440.100.090.04
Inventories20713784.3774.5746.8723.9617.38
Sundry debtors19915212381.5173.4860.3926.87
Cash & bank balances0.110.390.1311.710.231.151.27
Loans & advances38.7535.2731.7830.738.901.991.34
Total current assets44532523919912987.4946.86
Total current liabilities15895.4065.8797.1676.9746.7717.48
Net working capital28622917310152.5140.7229.38
Total assets43630821913560.4052.3040.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.390.1311.710.231.151.273.56
Net cash from operating activities(2.75)(33.18)9.69(28.79)(3.70)2.670.51
Net cash from investing activities(79.71)(20.24)(9.08)(25.65)(1.54)(1.35)(2.53)
Net cash from financing activities82.1853.68(12.18)65.934.31(1.44)(0.28)
Net change in cash(0.28)0.26(11.58)11.48(0.93)(0.11)(2.29)
Closing cash0.110.390.1311.710.231.151.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.8%+7.9%+0.9%+29.2%+84.7%+30.7%-
EBITDA growth+37.2%+58.0%+53.9%+34.3%+50.1%+52.9%-
PBT growth+52.4%+24.7%+58.9%+32.9%+99.4%+109.4%-47.7%
Net income growth+22.2%+58.6%+57.3%+35.3%+99.6%+110.2%-
Revenue CAGR (3Y)+13.1%+12.1%+34.0%+46.1%+36.9%+29.9%+38.8%
EBITDA CAGR (3Y)+49.4%+47.0%+45.9%+45.6%+36.1%+141.0%+98.4%
Profitability & leverage
Net income margin+3.3%+2.8%+2.4%+1.5%+1.5%+1.4%+0.9%
Return on capital employed+14.5%+14.4%+13.6%+15.2%+18.7%+14.6%+12.0%
Return on net worth+15.5%+13.2%+10.7%+10.8%+20.1%+12.6%+6.6%
Debt / equity1.621.170.660.491.151.190.91
Long-term debt / equity0.160.100.110.140.200.360.30
Interest cover55.5450.6642.2839.2233.6049.3961.68
Efficiency & per share
Fixed asset turnover9.2414.4819.8929.8236.1227.7034.41
Inventory turnover3.884.545.867.6010.089.3510.65
Debtors turnover3.803.654.555.955.334.435.61
EPS (β‚Ή)0.910.584.722.935.392.801.34
Dividend per share (β‚Ή)0.000.000.000.300.000.000.00
Book value per share (β‚Ή)6.195.2746.3841.9630.5523.5820.78

Investments & Acquisitions by Sudarshan Pharma

Sudarshan Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Ishwari Healthcare.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Medical supplies and consumables are manufactured in a range.
ishwarihealthcare.comMumbai, India1998Oct 2024β€’β€’β€’β€’
Premium access

Complete acquisition details for Sudarshan Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Sudarshan Pharma

4 dated milestones of Sudarshan Pharma across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded Sudarshan Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Ishwari Healthcare.
  4. Funding First funding round of $450K.

Web traffic of Sudarshan Pharma

The website of Sudarshan Pharma (sudarshanpharma.com) receives about 4.4K visits a month.

  • Monthly visits
    4.4K

    ▼ 73.6% vs previous month

Similar websites

Websites whose visitors overlap most with Sudarshan Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
balaxipharma.in
100%
1.9K#8,042,738View details

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Sudarshan Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Sudarshan Pharma

Premium access

Complete news archive for Sudarshan Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sudarshan Pharma

Sudarshan Pharma was founded in 2008 and raised its 1st funding round 16 years after it was founded.

Sudarshan Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Sudarshan Pharma has 24 employees.

The primary company behind Sudarshan Pharma, Sudarshan Pharma Industries Limited, reported revenue of β‚Ή712 Cr for FY 2026, up 39% year on year.

Sudarshan Pharma Industries Limited is involved in the production of pharmaceuticals and specialty chemicals. Operations are focused on active pharmaceutical ingredients (API), intermediates, and contract manufacturing. The company serves various sectors including healthcare and industrial applications. Solutions are provided for ethical divisions, generic supply, and institutional markets. Manufacturing facilities are located across multiple states in India, with distribution outlets in key regions. Exports of APIs and formulations are also managed to international markets.

Sudarshan Pharma offers Specialty Chemicals, API Manufacturing, Contract Manufacturing, and Intermediates Manufacturing.

Yes, Sudarshan Pharma is publicly traded on BSE under the ticker symbol SUDARSHAN.

Sudarshan Pharma has made 1 acquisition, including Ishwari Healthcare.

Sudarshan Pharma operates through Sudarshan Pharma Industries Limited.

The legal entities of Sudarshan Pharma currently have 9 directors, including Sachin Vasantrai Mehta, Jaya Ankur Singhania, Hemal Vasantrai Mehta and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available